Table 1 Association between EZH2 expression and the clinic-pathological characteristics of osteosarcoma patients.
From: Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma
Characteristics | EZH2 protein | ||
|---|---|---|---|
positive | Negative | Chi-square P-value | |
Age (years) | 0.486 | ||
11~20 | 14 | 20 | |
21~30 | 13 | 10 | |
≥31 | 12 | 11 | |
Gender | 0.385 | ||
Male | 24 | 29 | |
Female | 15 | 12 | |
Grade | 0.039* | ||
Low | 0 | 6 | |
High | 39 | 35 | |
Stage | <0.01* | ||
I | 0 | 6 | |
II | 26 | 35 | |
III | 13 | 0 | |
Local recurrence | 0.334 | ||
Yes | 9 | 6 | |
No | 30 | 35 | |
Lung metastasis | <0.01* | ||
Yes | 13 | 0 | |
No | 26 | 41 | |
Histological type | 0.173 | ||
Osteoblastic | 11 | 17 | |
Chondroblastic | 14 | 18 | |
Fibroblastic | 3 | 1 | |
Others | 11 | 5 | |
tumor size | 0.334 | ||
<10 cm | 30 | 35 | |
≥10 cm | 9 | 6 | |
